Rate My Professor Steven Bollipo

Bollipo's academic interests center on gastroenterology and hepatology, with emphasis on endoscopy training, quality improvement through initiatives like #Scopemanship, liver diseases including hepatitis B, cirrhosis, hepatocellular carcinoma (HCC), and non-alcoholic fatty liver disease (NAFLD, renamed MAFLD). He investigates the microbiome's role in liver cancer pathogenesis and addresses impacts of COVID-19 on endoscopy and liver disease management. He has produced 83 publications, cited over 1,209 times. Key publications include: “What’s in a name? Renaming ‘NAFLD’ to ‘MAFLD’” (2020, 389 citations); “Overview of guidance for endoscopy during the coronavirus disease 2019 pandemic” (2020, 199 citations); “Impact of COVID-19 on endoscopy trainees: an international survey” (2020, 112 citations); “Narrative review: Risk of eating disorders and nutritional deficiencies with dietary therapies for irritable bowel syndrome” (2022, 52 citations); “One world, one pandemic, many guidelines: management of liver diseases during COVID-19” (2020, 48 citations). Recent works cover HCC treatment outcomes, such as “Early-Stage Australian HCC Patients Treated at Tertiary Centres Show Comparable Survival Across Metropolitan and Non-Metropolitan Residency” (2026), “Initial Trans-Arterial Chemo-Embolisation (TACE) Is Associated with Similar Survival Outcomes as Compared to Upfront Percutaneous Ablation” (2024), and “Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC” (2023). Bollipo engages the academic community via social media (@stevenbollipo) and as a member of the European Society of Gastrointestinal Endoscopy (ESGE) social media working group, promoting discourse in #gitwitter and #livertwitter.